Antidepressant Effect of Dimeric Dipeptide GSB-106, an Original Low-Molecular-Weight Mimetic of BDNF

Cover Page

Abstract


A large amount of clinical and experimental data suggest the involvement of neurotrophins, in particular the brain-derived neurotrophic factor (BDNF), in depression pathogenesis. However, the therapeutic use of BDNF is limited because of its instability in biological fluids, poor blood-brain barrier (BBB) permeability, and the presence of side effects. A low-molecular-weight mimetic GSB-106, which is a substituted dimeric dipeptide bis(N-monosuccinyl-L-seryl-L-lysine)hexamethylenediamide, was designed and synthesized based on the BDNF fourth loop structure at the V.V. Zakusov Institute of Pharmacology (RAMS). GSB-106 was found to exhibit an antidepressant activity in various models of depressive-like state when administered intraperitoneally to outbred mice and rats. An effect for the substance, when administered daily for 4-5 days, was detected in the Porsolt forced swimming test (0.1 and 1.0 mg/kg) and in the tail suspension test in mice (1.0 and 1.5 mg/ kg). An effect for GSB-106 at doses of 0.1 and 0.5 mg/kg was observed after a single application in experiments on rats in the Nomura water wheel test. The obtained evidence supports the hypothesis on the involvement of BDNF in the pathogenesis of various depression conditions, thus opening prospects for searching for new original antidepressants.


S. B. Seredenin

V.V.Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences

Email: t_garibova@mail.ru

Russian Federation

T. A. Voronina

V.V.Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences

Email: t_garibova@mail.ru

Russian Federation

T. A. Gudasheva

V.V.Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences

Email: t_garibova@mail.ru

Russian Federation

T. L. Garibova

V.V.Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences

Author for correspondence.
Email: t_garibova@mail.ru

Russian Federation

G. M. Molodavkin

V.V.Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences

Email: t_garibova@mail.ru

Russian Federation

S. A. Litvinova

V.V.Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences

Email: t_garibova@mail.ru

Russian Federation

О. A. Elizarova

V.V.Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences

Email: t_garibova@mail.ru

Russian Federation

V. I. Poseva

V.V.Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences

Email: t_garibova@mail.ru

Russian Federation

  1. // 10 facts about the global burden of disease. // WHO Bulletin. 2008, url www.who.int/features/factfiles/global_burden/ ru/index.html
  2. Sartorius N. // Med. Res. 2001, V.1, P.20-21
  3. Wittchen H.U. // V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2005, №4, P.42-46
  4. Angelucci F., Mathe A.A., Aloe L. // Progress in Brain Research. 2004, V.146, P.151-165
  5. Yu H., Chen Z.Y. // Acta Pharmacologica Sinica. 2011, V.32, P.3-11
  6. Neto F.L., Borges G., Torres-Sanchez S., Mico J.A., Berrocoso E. // Current Neuropharmacology. 2011, №9, P.530-552
  7. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. // Psychiatry Res. 2002, V.109, P.143-148
  8. Chen B., Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. // Biological Psychiatry 2001, V.50, P.260-265
  9. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. // Pharmacol. Biochem. Behav. 1997, V.56, P.131-137
  10. Shirayama J., Chen A.C., Nakagawa S., Russel R.S., Duman R.S. // J. Neurosci. 2002, V.22, P.3251-3261
  11. Govindarajan A., Rao B.S.S., Nair.D I.O., Trinh M., Mawjee N., Tonegawa S., Chattarji S. // Proc. Natl. Acad. Sci. USA 2006, P.13208-13213
  12. Siuciak J.A., Altar C.A., Wiegand S.J., Lindsay R.M. // Brain Res. 1994, V.663, P.326-330
  13. O’Leary P.D., Huges R.A. // J. Biol. Chem. 2003, V.278, P.25738-25744
  14. Massa S.M., Yang T., Xie Y., Shi J., Bilgen M., Joyce J.N., Nehama D., Rajadas J., Longo F.M. // J. Clin. Investigation. 2010, V.120, P.1774-1785
  15. Seredenin S.B., Gudasheva T.A. // Patent RU S № 2410392 of 16.02.2009 priority. 2011
  16. Gudasheva T.A., Tarasyuk A.V., Pomogaybo S.V., Logvinov I.O., Povarnina P.Y., Antipova T.A., Seredenin S.B. // Bioorganic Chemistry. 2012, V.38, P.280-290
  17. Logvinov I.O., Antipova T.A., Gudasheva T.A., Tarasyuk A.V., Antipov P.I., Seredenin S.B. // Bull.Exp.Biol.Med. 2013
  18. Porsolt B.D., Bertin A., Jalfre M. // Europ. J. Pharmacol. 1978, V.51, P.291-294
  19. Nomura S., Shimizu J., Kinjo M., Kametani H., Nakazava T. // Eur. J. Pharmacol. 1982, V.83, P.171-175
  20. Steru L., Chermat R., Thierry B., Simon P. // Psychopharmacology. 1985, V.85, P.367-370
  21. Molodavkin G.M., Voronina T.A., Mdzinarishvili A.L. // Exp. Cl. Pharm. 1994, V.1, P.3-5
  22. Schmidt H.D., Duman R.S. // Neuropsychopharmacology. 2010, V.35, P.2378-2391
  23. Gudasheva T.A., Logvinov I.O., Antipova T.A., Seredenin S.B. // DAS. 2013, V.451, №5, P.577-583

Views

Abstract - 304

PDF (English) - 133

PDF (Russian) - 109

Cited-By


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2013 Seredenin S.B., Voronina T.A., Gudasheva T.A., Garibova T.L., Molodavkin G.M., Litvinova S.A., Elizarova E.A., Poseva V.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies